Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.46439/Neuroscience.3.016
The role of aromatic stacking in drug-drug interactions
Amina S Woods1,*
- 1NIDA IRP, NIH Structural Biology Unit Integrative Neuroscience Branch, 333 Cassell Drive, Baltimore, Maryland 21224, USA
- 2The Johns Hopkins University School of Medicine, Pharmacology and Molecular Sciences, Baltimore, MD 21205, USA
Corresponding Author
Amina S Woods, awoods@intra.nida.nih.gov
Received Date: July 26, 2021
Accepted Date: September 17, 2021
Woods AS. The role of aromatic stacking in drug-drug interactions. Neurosci Chron. 2022; 3(1):1-2
Copyright: © 2022 Woods AS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
The role of aromatic stacking in drug-drug interactions
Having studied and worked in the fields of pharmacology and structural biology my first reaction to reading an article or attending a lecture about a class of chemical compounds or biomolecules regardless of whether they are nucleotides, proteins or lipids is to look up their structure or sequence, as the chemical structure of molecules is what defines their character, that is their mechanism of action. Most cancer therapeutic agents such as Taxol (paclitaxel) which is widely used to target solid tumors are rich in aromatic structures. These patients are often depressed and are on psychotropic medications, which also contain two or more aromatics. It is unknown whether these two groups of compounds directly interact.
Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel
Discovered in a large-scale screening of natural plant chemicals, Taxol/paclitaxel and the taxane family of compounds are surprisingly successful anti-cancer drugs, used in treatment of the majority of solid tumors, and especially suitable for metastatic and recurrent cancer. Paclitaxel is often used in combination with platinum agents and is administrated in a dose dense regimen to treat recurrent cancer.